Výsledky vyhledávání

Akademický článek

Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response

Autor: Habib Sadeghirad, James Monkman, Chin Wee Tan, Ning Liu, Joseph Yunis, Meg L. Donovan, Afshin Moradi, Niyati Jhaveri, Chris Perry, Mark N. Adams, Ken O’Byrne, Majid E. Warkiani, Rahul Ladwa, Brett G.M. Hughes, Arutha Kulasinghe

Publikováno v: Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)

Abstract Background Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) generally has a poor prognosis for patients with limited treatment options. While incorporating immune checkpoint inhibitors (ICIs) has now become the standard

Externí odkaz: https://doaj.org/article/f1dddeab14594adbaeaca19710053a73

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Autor: Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)

Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d

Externí odkaz: https://doaj.org/article/50d39c846b474baea88547c6b345e6aa

Zobrazit plný text záznamu

Akademický článek

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC

Autor: Marliese Alexander, B.Pharm(Hons), MPH, PhD, Joe Wei, MD, Sagun Parakh, MD, Thomas John, MD, Steven Kao, MD, Adnan Nagrial, MD, Samantha Bowyer, MD, Lydia Warburton, MD, Melissa Moore, MD, Brett G.M. Hughes, MD, Timothy D. Clay, MD, Nick Pavlakis, MD, Benjamin J. Solomon, MD, Malinda Itchins, MD

Publikováno v: JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100490- (2023)

Introduction: Over the past decade, ALK tyrosine kinase inhibitors have delivered unprecedented survival for individuals with ALK-positive (ALK+) lung cancers. Real-world data enhance the understanding of optimal drug sequencing and expectations for

Externí odkaz: https://doaj.org/article/62a74cb698b1419b955b790acab4a2a3

Zobrazit plný text záznamu

Akademický článek

A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer

Autor: M. S. Brose, Yu. Panaseykin, B. Konda, C. de la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor

Publikováno v: Опухоли головы и шеи, Vol 12, Iss 1, Pp 86-98 (2022)

Введение. Ленватиниб является мультикиназным ингибитором, одобренным для лечения радиойодрефрактерного дифференцированного рака щит�

Externí odkaz: https://doaj.org/article/d7a35ee1dee346c98829477eec0b69b8

Zobrazit plný text záznamu

Akademický článek

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

Autor: Joanna Kapeleris, Juliana Müller Bark, Shanon Ranjit, Darryl Irwin, Gunter Hartel, Majid Ebrahimi Warkiani, Paul Leo, Connor O'Leary, Rahul Ladwa, Kenneth O'Byrne, Brett G.M. Hughes, Chamindie Punyadeera

Publikováno v: Heliyon, Vol 8, Iss 7, Pp e09971- (2022)

Background: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a medi

Externí odkaz: https://doaj.org/article/11794cb68225483fa0ba364384b113a6

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání